BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma. Issue 5 (16th April 2019)

• Record Type: Journal Article
• Authors: Ito, Yoshikazu; Umezu, Tomohiro; Tadokoro, Kenichi; Saito, Yuu; Katagiri, Seiichiro; Suguro, Tamiko; Asano, Michiyo; Yoshizawa, Seiichiro; Akahane, Daigo; Tanaka, Yuko; Fujimoto, Hiroaki; Okabe, Seiichi; Gotoh, Moritaka; Tauchi, Tetsuzo; Kawana, Chiaki; Ohyashiki, Junko H.; Nakamura, Naoya; Ohyashiki, Kazuma
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 5(2019)
• Page Start: 1283
• Page End: 1288
• Publication Date: 2019-04-16
• Subjects: BIM deletion polymorphism -- follicular lymphoma -- female -- progression-free survival -- epidemiology; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1529310
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Deletion polymorphism of BCL-2-like protein 11 ( BIM ) is specifically found in East Asia. To explain some epidemiological discrepancies between Asian and Western countries, we analyzed a silent single nucleotide polymorphism (SNP) in exon 5 (c465C > T) and a deletion site (2903 bp) in intron 2 in 77 patients with follicular lymphoma by the Q-invader method using PCR. In females, 5-year progression-free survivals (PFS) were 20.0% in the BIM deletion group, 66.7% in the SNP group and 81.5% in the wild-type (WT) group ( p = .0012). In the WT group, 5-year PFS was 40.4% in males ( p = .0448 vs. female PFS). This tendency was strengthened in patients receiving rituximab (26.9% vs. 84.2%, p = .006). Superior PFS in the WT females in Japan was comparable with the results of cohort studies in the United States and Sweden. Favorable prognosis in Japanese females may be masked by the BIM deletion polymorphism.